Literature DB >> 11121836

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.

G J Murphy1, J C Holder.   

Abstract

The recent development of a novel class of insulin-sensitizing drugs, the thiazolidinediones (TZDs), represents a significant advance in antidiabetic therapy. One key mechanism by which these drugs exert their effects is by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma), a member of the nuclear receptor family. Evidence supporting this mechanism of action of the TZDs will be reviewed in this article. Recent data suggests that PPAR-gamma agonists might also have therapeutic potential in the treatment of inflammatory diseases and certain cancers.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11121836     DOI： 10.1016/s0165-6147(00)01559-5

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  72 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Differentially expressed genes in PPARγ-deficient MSCs.

Authors:  Yun Su; Xiaona Shen; Jie Chen; Carlos M Isales; Jing Zhao; Xing-Ming Shi
Journal:  Mol Cell Endocrinol       Date:  2017-07-31       Impact factor: 4.102

3.  Iso-α-acids, Bitter Components of Beer, Prevent Inflammation and Cognitive Decline Induced in a Mouse Model of Alzheimer's Disease.

Authors:  Yasuhisa Ano; Atsushi Dohata; Yoshimasa Taniguchi; Ayaka Hoshi; Kazuyuki Uchida; Akihiko Takashima; Hiroyuki Nakayama
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

4.  High fat diet reduces the expression of glutathione peroxidase 3 in mouse prostate.

Authors:  Yoshitaka Sekine; David Osei-Hwedieh; Kant Matsuda; Nalini Raghavachari; Delong Liu; Yosuke Furuya; Hidekazu Koike; Kazuhiro Suzuki; Alan T Remaley
Journal:  Prostate       Date:  2011-03-03       Impact factor: 4.104

Review 5.  New pharmacologic agents for diabetes.

Authors:  C J Bailey
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

6.  15-Deoxy-delta12,14-PGJ2: endogenous PPARgamma ligand or minor eicosanoid degradation product?

Authors:  William S Powell
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

7.  Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Authors:  Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Nimesh S A Patel; Rosanna Di Paola; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

8.  Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells.

Authors:  Chan Woo Cheon; Dae Hwan Kim; Dong Heon Kim; Yong Hoon Cho; Jae Hun Kim
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

9.  The fat-1 transgene in mice increases antioxidant potential, reduces pro-inflammatory cytokine levels, and enhances PPAR-gamma and SIRT-1 expression on a calorie restricted diet.

Authors:  Mizanur Rahman; Ganesh V Halade; Arunabh Bhattacharya; Gabriel Fernandes
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

10.  Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells.

Authors:  Wenli Zhang; Zhong-Liang Deng; Liang Chen; Guo-Wei Zuo; Qing Luo; Qiong Shi; Bing-Qiang Zhang; Eric R Wagner; Farbod Rastegar; Stephanie H Kim; Wei Jiang; Jikun Shen; Enyi Huang; Yanhong Gao; Jian-Li Gao; Jian-Zhong Zhou; Jinyong Luo; Jiayi Huang; Xiaoji Luo; Yang Bi; Yuxi Su; Ke Yang; Hao Liu; Hue H Luu; Rex C Haydon; Tong-Chuan He; Bai-Cheng He
Journal:  PLoS One       Date:  2010-07-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.